Abstract:
En
|
Text:
En
|
PDF:
En
Abstract Introduction and objectives: Myofascial Pain Syndrome (MPS) of the Quadratus Lumborum muscle (QL) is a frequent cause of chronic low back pain. With this study, we aimed to assess the efficacy of ultrasound-guided infiltration with 0.25% levobupivacaine and 40 mg triamcinolone for MPS of the QL. Methods: Observational and retrospective study of participants submitted to ultrasound-guided infiltration of the QL muscle from January 1, 2015 to June 31, 2019. Pain intensity was assessed using the five-point pain Numeric Rating Scale (NRS): pre-intervention, at 72 hours, 1 month, 3 months and 6 months post-intervention. Additional data collected were demographic characteristics, opioid consumption, and adverse effects. Results: We assessed 90 participants with mean age of 55.2 years. Sixty-eight percent of participants were female. Compared to the pre-intervention assessment, there was an improvement in pain at 72 hours (Mean Difference [MD = 3.085]; 95% CI: 2.200-3.970, p < 0.05), at the 1st month (MD = 2.644; 95% CI: 1.667-3.621, p < 0.05), at the 3rdmonth (MD = 2.017; 95% CI: 0.202-2.729, p < 0.05) and at the 6th month (MD = 1.339; 95% CI 0.378-2.300, p < 0.05), post-intervention. No statistically significant differences in opioid consumption were observed. No adverse effects associated with the technique were reported. Conclusions: Ultrasound-guided infiltration of the QL muscle is a safe and effective procedure for the treatment of pain in the QL MPS within 6 months post-intervention. objectives (MPS (QL ultrasoundguided ultrasound guided 025 0 25 0.25 4 Methods 201 31 2019 fivepoint five point NRS (NRS) preintervention, preintervention pre intervention, intervention 7 postintervention. postintervention post intervention. post-intervention characteristics Results 9 552 55 2 55. years Sixtyeight Sixty eight female assessment Mean MD 3.085 3085 085 3.085] 95 2.2003.970, 22003970 2.200 3.970, 200 970 2.200-3.970 0.05, 005 0.05 , 05 st 2.644 2644 644 1.6673.621, 16673621 1.667 3.621, 667 621 1.667-3.621 rdmonth 2.017 2017 017 0.2022.729, 02022729 0.202 2.729, 202 729 0.202-2.729 th 1.339 1339 339 0.3782.300, 03782300 0.378 2.300, 378 300 0.378-2.300 observed reported Conclusions Ultrasoundguided Ultrasound 02 0.2 20 (NRS 5 3.08 308 08 2003 2.2003.970 2200397 2200 2.20 3970 3.970 97 2.200-3.97 00 0.0 2.64 264 64 6673 1.6673.621 1667362 1667 1.66 3621 3.621 66 62 1.667-3.62 2.01 01 2022 0.2022.729 0202272 0202 0.20 2729 2.729 0.202-2.72 1.33 133 33 3782 0.3782.300 0378230 0378 0.37 2300 2.300 37 30 0.378-2.30 0. 3.0 2.2003.97 220039 220 2.2 397 3.97 2.200-3.9 2.6 26 1.6673.62 166736 166 1.6 362 3.62 1.667-3.6 2.0 0.2022.72 020227 020 272 2.72 0.202-2.7 1.3 13 0.3782.30 037823 037 0.3 230 2.30 0.378-2.3 3. 2.2003.9 22003 22 2. 39 3.9 2.200-3. 1.6673.6 16673 16 1. 36 3.6 1.667-3. 0.2022.7 02022 27 2.7 0.202-2. 0.3782.3 03782 03 23 2.3 0.378-2. 2.2003. 2.200-3 1.6673. 1.667-3 0.2022. 0.202-2 0.3782. 0.378-2 2.2003 2.200- 1.6673 1.667- 0.2022 0.202- 0.3782 0.378-